Patients with lower extremity dialysis access have poor primary patency and survival.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
12 2019
Historique:
received: 17 12 2018
accepted: 04 03 2019
pubmed: 31 5 2019
medline: 4 6 2020
entrez: 1 6 2019
Statut: ppublish

Résumé

Lower extremity arteriovenous (AV) access is an alternative when upper extremity access options have been exhausted. Our goal was to assess short- and medium-term outcomes of lower extremity hemodialysis access. The Vascular Quality Initiative was reviewed for all lower extremity AV hemodialysis cases. Patient and case details were recorded. Multivariable analysis was used to analyze outcomes. We identified 463 lower extremity AV access cases in the VQI registry. There were 56 AVF (12.1%) and 407 AVG (87.9%). The mean age was 56 ± 15 years, 46.9% were male, and 40.7% were Caucasian. The majority (90%) had a previous upper extremity AV access and 25.4% had a prior lower extremity access. More than one-half (57.9%) had a tunneled line at the time of the procedure. Patients undergoing an AVF vs AVG creation were younger, more often ambulatory, and less often with peripheral arterial disease. For AVF, the superficial femoral artery was more often used for access inflow (76.8% vs 49.4%; P < .001), compared with AVG, and there was no difference in using femoral vein as the main outflow (78.6% vs 82.6%; P = .466). For AVF, compared with AVG, there was no difference in wound infection (12.5% vs 9.6%; P = .571), ischemic steal (5% vs 2.2%; P = .273), or leg swelling (2.5% vs 3.3%; P = .99) at 6 months. Kaplan-Meier analysis of the overall cohort showed that freedom from loss of primary patency at 6 months was 52.9%, freedom from any reintervention at 6 months was 75.3%, and the 1-year survival was 81.9%. Survival at 5 years was 65.5%. Multivariable analysis showed no significant association of access type (AVF vs AVG) with primary patency loss or death (hazard ratio [HR], 0.74; 95% confidence interval [CI], 0.36-1.5; P = .4), any reintervention or death (HR, 1.65; 95% CI, 0.82-3.33; P = .163), or mortality (HR, 1.94; 95% CI, 0.71-5.33; P = .197). Factors independently associated with primary patency loss or death included peripheral arterial disease (HR, 1.6; 95% CI, 1.06-2.42; P = .03) and obesity (HR, 1.5; 95% CI, 1.1-2.05; P = .01). Any reintervention or death was associated with obesity (HR, 1.67; 95% CI, 1.09-2.56; P = .015). Mortality was associated with congestive heart failure (HR, 1.82; 95% CI, 1.13-2.94; P = .015) and white race (HR, 1.71; 95% CI, 1.08-2.73; P = .023). In our contemporary multicenter analysis, patients undergoing lower extremity AV access creation have low primary access patency and almost 20% mortality at 1 year. These results should be considered when suggesting a lower extremity dialysis access, as well as other dialysis alternatives when available.

Identifiants

pubmed: 31147128
pii: S0741-5214(19)30534-8
doi: 10.1016/j.jvs.2019.03.037
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1913-1918

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Steven L Pike (SL)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass.

Alik Farber (A)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass.

Nkiruka Arinze (N)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass.

Scott Levin (S)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass.

Thomas W Cheng (TW)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass.

Douglas W Jones (DW)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass.

Tze-Woei Tan (TW)

Division of Vascular Surgery, University of Arizona, College of Medicine, Tucson, Ariz.

Mahmoud Malas (M)

Division of Vascular and Endovascular Surgery, University of California, San Diego, Calif.

Denis Rybin (D)

Boston University, School of Public Health, Boston, Mass.

Jeffrey J Siracuse (JJ)

Division of Vascular and Endovascular Surgery, Boston Medical Center, Boston University, School of Medicine, Boston, Mass. Electronic address: jeffrey.siracuse@bmc.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH